Hence, Spotify is growing but not making money. Moreover, the subscriber base growth justifies the risk Spotify (SPOT) took by paying $100 million for The Joe Rogan Experience.
Hence, Centene (NYSE: CNC) serves the largest segment of American health insurance, Medicaid. In particular, Centene serves almost one million Medicare beneficiaries though Medicare Advantage, Medicare Supplement, Special Needs, and Medicare-Medicaid (MMP) plans.Read more
To elaborate, the Texas Pacific Land Corporation (TPL) is one of the biggest landowners in Texas. Mr. Market is bullish on Texas. Texas Pacific’s share price rose from $459.56 on 21 September 2020 to $1,307.40 on 23 September 2020.Read more
Importantly, Advance’s revenues are growing. Stockrow estimates Advance Auto’s revenues grew by 12.01% in the quarter ending on 31 July 2021. In contrast, Advance Auto Parts’ revenues grew from 18.38% on 31 July 2020.Read more
Thus Penn National (NASDAQ: PENN) can show us if online sportsbooks make money. Notably, Penn’s quarterly gross profit has exploded over the past year.Read more
Consequently, many more people began using Spotify for music and podcasts. Thus, Spotify’s growth could have little to do with Rogan.
I think Mr. Market prices Moderna (NASDAQ: MRNA) fairly. I believe the financial numbers and the growth justify the $185.01 Mr. Market paid for Moderna on 28 May 2021.Read more
Nanox’s management claims they have a better x-ray technology known as Cold Cathode. A Cold Cathode is a cathode ray tube that is not electrically heated by a filament.Read more
Coursera claims to be the largest provider of MOOCs. In particular, Coursera offers MOOCs from some of the biggest names in education, including Yale and Princeton.Read more
Merck (MRK) will manufacture the controversial Johnson & Johnson (JNJ) single-shot vaccine, U.S. President Joe Biden (D-Delaware) announced on 3 March 2021. Biden hopes Merck and J&J could manufacture enough vaccine for every adult in the United States by May 2021.
The contract could be lucrative because there were 255.2 million adults in the United States in 2019. However, the Johnson & Johnson (NYSE: JNJ) vaccine is controversial because it is weaker.